Evanthia Roussos Torres, MD, PhD

Assistant Professor of Medicine and Cancer Biology

Program Leader for Tumor Immunology and Microenvironment (TIME) Program

Image of Evanthia Roussos Torres, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Roussos Torres received a BS in Microbiology, Immunology and Molecular Genetics and a BA in World Arts and Cultures with a concentration in Dance from the University of California at Los Angeles (UCLA). She then went on to receive her combined MD/PhD from the Medical Scientist Training Program at the Albert Einstein College of Medicine in New York. She then completed her internal medicine residency at the Hospital of the University of Pennsylvania and her hematology/ oncology fellowship training at the University of Pennsylvania and Johns Hopkins University. Dr. Roussos Torres graduated from fellowship and began her faculty career as an Assistant Professor at Johns Hopkins University and is now an Assistant Professor at the University of Southern California where she leads her own lab and works collaboratively with other physicians and physician scientists to continue her work in immune-oncology with a specific interest in breast cancer and the tumor immune suppressive microenvironment.

Dr. Roussos Torres is very passionate about her research as well as her care of patients with cancer and training of the fellows to become compassionate and knowledgeable physicians. She is driven to make memorable contributions to the field of cancer research given her personal experience advocating for her mother who died from metastatic breast cancer in 2016. Dr. Roussos Torres felt passionate about having an impact on the field of breast cancer prior to her mother’s diagnosis but learning about the devastation of metastatic disease as the family member of a patient provided a different perspective and drive for novel treatment options.

Dr. Roussos Torres loves her work but also prioritizes her family life; her husband Dr. Stephen Torres is an orthopedic surgeon, specializing in sports medicine and together they have three sons, Owen, James and Luke who fill their life with joy and make every day a wonder! The Torres family also has a Chesapeake Bay retriever, Emma who greatly contributes to her active lifestyle! Dr. Roussos Torres enjoys traveling, eating out at new restaurants and road biking! Dr. Roussos Torres grew up in Santa Monica and is so happy to work close to where she grew up to raise her family near her siblings, their families, and her father who still resides here.

Laboratory website: https://sites.usc.edu/roussostorreslab/

Publications library: https://www-ncbi-nlm-nihgov.libproxy2.usc.edu/myncbi/1pwdQqmmnMeUHt/bibliography/public/

Publications

  • Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 2021 08 24; 36(8):109599.. View in PubMed
  • Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clin Cancer Res. 2021 11 01; 27(21):5828-5837.. View in PubMed
  • Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. Front Mol Biosci. 2021; 8:674558.. View in PubMed
  • Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene. 2021 May; 40(18):3187-3200.. View in PubMed
  • Adopting an alternative structure for clinical trials in immunotherapy. Expert Rev Anticancer Ther. 2021 04; 21(4):373-375.. View in PubMed
  • Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncol Pract. 2020 Oct; 16(10):665-674.. View in PubMed
  • Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 2020 05 14; 9(1):1760685.. View in PubMed
  • Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-16.. View in PubMed
  • Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Front Bioeng Biotechnol. 2020; 8:141.. View in PubMed
  • Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data. Cancer Res. 2019 10 01; 79(19):5102-5112.. View in PubMed